Mount Sinai's Murrough presented historical data showing that while cardiology, for example, has seen a large increase in the number of different mechanisms that heart drugs target, that number has remained essentially unchanged for both depression and schizophrenia

Mount Sinai's Murrough presented historical data showing that while cardiology, for example, has seen a large increase in the number of different mechanisms that heart drugs target, that number has remained essentially unchanged for both depression and schizophrenia

The Garvan Institute of Medical Research and Cancer Therapeutics CRC Pty Ltd., of Melbourne, Australia, signed a license agreement with SYNkinase Pty Ltd., also of Melbourne, to develop and market a pan-kinase binding agent to help screen human cells and tissues and to identify potential drug targets in diseased states

Although they do not directly identify drug targets or cell populations that could be used to fight chronic infections, the findings, corresponding author Dietmar Zehn told BioWorld Today, "create a different way of thinking" about what T cells are up to in chronic infections – one that could ultimately change the practical approaches toward such infections

Our drugs target a different part of the pathway of abnormal protein folding that occurs with cystic fibrosis," he explained

G protein-coupled receptors and kinases "have been very actively pursued as drug targets for good reasons

Total Value in 2013: $5,960.77M* Number of Deals in 2013: 93 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date FEBRUARY Ablynx NV (Ghent, Belgium) Spirogen Ltd. (London) ND Research collaboration to evaluate the potential of a cancer drug conjugate combining Spirogen's cytotoxic drugs, pyrrolobenzodiazepines and associated linker technology, with Nanobodies generated Ablynx will provide access to Nanobodies against an undisclosed target, and Spirogen will

Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date DECEMBER Cevec Pharmaceuticals GmbH (Cologne, Germany) Yuhan Corp. (Seoul, South Korea) ND CAP-Technology licensing deal enabling Yuhan to use Cevec's CAP-T and CAP cell expression systems for the production and development of various therapeutic proteins Financial terms were not disclosed 12/21/12 GlaxoSmithKline plc (London) The University of Texas MD Anderson Cancer Center (Houston) $335 Research

Atox Bio Ltd., of Ness Ziona, Israel, said data from an animal model of necrotizing soft-tissue infection, also known as flesh-eating bacteria, demonstrated that the administration of a single dose of AB103, given several hours after infection even without antibiotics, increased survival in animals and reduced tissue necrosis, inflammation and bacterial burden at the site of infection without compromising the immune response. AB103, a rationally designed short peptide designed to modulate the

Proteros biostructures GmbH, of Martinsried, Germany, and Priaxon AG, of Munich, Germany, signed a deal to jointly develop lead compounds for protein-protein interaction (PPI) drug targets

drug targets, develop new therapeutics and evaluate them in proof-of-concept trials 12/14/12 Genisphere Inc. (Hatfield, Pa.) Lankenau Institute for Medical Research Partnership To develop nanotherapeutic products for cancers and eye diseases The two organizations have an existing collaboration in the area of inflammatory bowel disease biomarkers centered on Genisphere's 3DNA dendrimer technology for delivery of a variety of therapeutic agents to cells 12/4/12 Gentium SpA (Villa Guardia, Italy

to go after new drug targets that are not druggable today, using either small or large molecules," Bancel said

Takeda Pharmaceutical Co., of Tokyo, and the Scripps Research Institute announced plans to expand their recent research collaboration to search for new drug targets for a variety of diseases

By Sharon Kingman Staff Writer LONDON – Study of a family affected by an inherited neurological disease has helped to reveal the identity of an enzyme that could point the way to new therapies for cancer and cardiovascular disease. The existence of the enzyme, which plays a role in maintaining cell survival and DNA repair, has been predicted for at least 30 years and has even been shown to operate in cell cultures. But, until it was linked with the gene defect in the family studied, no one knew

LONDON – Study of a family affected by an inherited neurological disease has helped to reveal the identity of an enzyme that could point the way to new therapies for cancer and cardiovascular disease. The existence of the enzyme, which plays a role in maintaining cell survival and DNA repair, has been predicted for at least 30 years and has even been shown to operate in cell cultures. But, until it was linked with the gene defect in the family studied, no one knew what it was. Now an

They showed that Herceptin's effects on bone marrow metastases were independent of the HER2 signaling pathway, and that the drug targets cancer stem cells, interfering with their self-renewal

Rather than looking to see what effect compounds might induce in animal models, tissues and cells, the industry became fixated on looking for drug molecules with the ability to interact with isolated protein drug targets in vitro

Zymeworks said the Azymetric platform is an IgG1-based heterodimeric antibody scaffold that consists of two different heavy chains engineered to exclusively assemble into a single molecule, allowing bispecific binding to two different antigens or drug targets

They concluded that beyond the specific rabies drug candidates they identified, their studies "suggest the existence of labile assembly machines that can be rendered accessible as next-generation drug targets" by their methods